Decreased urinary level of melatonin as a marker of disease severity in patients with multiple sclerosis

Iranian Journal of Allergy, Asthma and Immunology

Volumn 14, Issue 1, 2015, Pages 91-97

  Gholipour, Taha ^a,b   Ghazizadeh, Taher ^a,b   Babapour, Sahand ^a,b   Mansouri, Behzad ^c   Ghaffarpour, Majid ^a   Siroos, Bahaadin ^a   Harirchian, Mohammad Hossein ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cognitive function; Melatonin; Multiple sclerosis

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; MELATONIN; 6-SULFATOXYMELATONIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE SCORE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; URINE LEVEL; ANALOGS AND DERIVATIVES; ENZYME LINKED IMMUNOSORBENT ASSAY; URINE;

ADULT; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MELATONIN; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84908565743     PISSN: 17351502     EISSN: 17355249     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Dhib-Jalbut S. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. Neurology 2007; 68 (22 Suppl 3) : S13-21.
2. Racke MK. The role of B cells in multiple sclerosis: Rationale for B-cell-targeted therapies. Curr Opin Neurol 2008; 21 (Suppl 1) : S9-S18.
3. Richter HG, Torres-Farfan C, Garcia-Sesnich J, Abarzua-Catalan L, Henriquez MG, Alvarez-Felmer M, et al. Rhythmic expression of functional MT1 melatonin receptors in the rat adrenal gland. Endocrinology 2008; 149 (3) : 995-1003.
4. Maestroni GJ, Conti A. Immuno-derived opioids as mediators of the immuno-enhancing and anti-stress action of melatonin. Acta Neurol (Napoli) 1991; 13 (4) : 356-60.
5. Orbach H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev 2007; 6 (8) : 537-42.
6. Sandyk R. Diurnal variations in vision and relations to circadian melatonin secretion in multiple sclerosis. Int J Neurosci 1995; 83 (1-2) : 1-6.
7. Constantinescu CS. Melanin, melanocyte-stimulating hormone, and the susceptibility to autoimmune demyelination: A rationale for light therapy in multiple sclerosis. Med Hypotheses 1995; 45 (5) : 455-8.
8. Lorton D, Lubahn CL, Estus C, Millar BA, Carter JL, Wood CA, et al. Bidirectional communication between the brain and the immune system: Implications for physiological sleep and disorders with disrupted sleep. Neuroimmunomodulation 2006; 13 (5-6) : 357-74.
9. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP. Light suppresses melatonin secretion in humans. Science 1980; 210 (4475) : 1267-9.
10. Macchi MM, Bruce JN. Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol 2004; 25 (3-4) : 177-95.
11. Reiter RJ, Tan DX, Manchester LC, Tamura H. Melatonin defeats neurally-derived free radicals and reduces the associated neuromorphological and neurobehavioral damage. J Physiol Pharmacol 2007; 58 (Suppl 6) : 5-22.
12. Ayre EA, Pang SF. 2-[125I]iodomelatonin binding sites in the testis and ovary: Putative melatonin receptors in the gonads. Biol Signals 1994; 3 (2) : 71-84.
13. Brown GM, Pang CS, Pang SF. Binding sites for 2-[125I]iodomelatonin in the adrenal gland. Biol Signals 1994; 3 (2) : 91-8.
14. Guerrero JM, Reiter RJ. Melatonin-immune system relationships. Curr Top Med Chem 2002; 2 (2) : 167-79.
15. Wrona D. Neural-immune interactions: An integrative view of the bidirectional relationship between the brain and immune systems. J Neuroimmunol 2006; 172 (1-2) : 38-58.
16. Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR, Rafii-El-Idrissi M, Sanchez-Margalet V, Goberna R, et al. Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: A possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J Immunol 1997; 159 (2) : 574-81.
17. Carrillo-Vico A, Lardone PJ, Alvarez-Sánchez N, Rodríguez-Rodríguez A, Guerrero JM. Melatonin: Buffering the immune system. Int J Mol Sci 2013; 14 (4) : 8638-83.
18. Pioli C, Caroleo MC, Nistico G, Doria G. Melatonin increases antigen presentation and amplifies specific and non specific signals for T-cell proliferation. Int J Immunopharmacol 1993; 15 (4) : 463-8.
19. Nelson RJ, Demas GE. Role of melatonin in mediating seasonal energetic and immunologic adaptations. Brain Res Bull 1997; 44 (4) : 423-30.
20. Lissoni P, Rovelli F, Meregalli S, Fumagalli L, Musco F, Brivio F, et al. Melatonin as a new possible anti-inflammatory agent. J Biol Regul Homeost Agents 1997; 11 (4) : 157-9.
21. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27 (2) : 189-200.
22. Maestroni GJ, Conti A. Anti-stress role of the melatonin-immuno-opioid network: Evidence for a physiological mechanism involving T cell-derived, immunoreactive beta-endorphin and MET-enkephalin binding to thymic opioid receptors. Int J Neurosci 1991; 61 (3-4) : 289-98.
23. Whitacre CC, Dowdell K, Griffin AC. Neuroendocrine influences on experimental autoimmune encephalomyelitis. Ann N Y Acad Sci 1998; 840: 705-16.
24. Marrie RA. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol 2004; 3 (12) : 709-18.
25. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58 (6) : 840-6.
26. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) . Neurology 1983; 33 (11) : 1444-52.
27. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12 (3) : 189-98.
28. Ansari NN, Naghdi S, Hasson S, Valizadeh L, Jalaie S. Validation of a Mini-Mental State Examination (MMSE) for the Persian Population: A Pilot Study. Appl Neuropsychol 2010; 17 (3) : 190-5.
29. Harirchian MH, Nasergivechi S, Maddah M, Meysamie A, Amini H, Shandiz EE, et al. modified fatigue impact scale in Iranian patients with multiple sclerosis. Iran J Neurol 2013; 12 (1) : 32-4.
30. Krupp LB, Elkins LE. Fatigue and declines in cognitive functioning in multiple sclerosis. Neurology 2000; 55 (7) : 934-9.
31. Constantinescu CS, Hilliard B, Ventura E, Rostami A. Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis. Pathobiology 1997; 65 (4) : 190-4.
32. Kang JC, Ahn M, Kim YS, Moon C, Lee Y, Wie MB, et al. Melatonin ameliorates autoimmune encephalomyelitis through suppression of intercellular adhesion molecule-1. J Vet Sci 2001; 2 (2) : 85-9.
33. Sandyk R. Influence of the pineal gland on the expression of experimental allergic encephalomyelitis: Possible relationship to the aquisition of multiple sclerosis. Int J Neurosci 1997; 90 (1-2) : 129-33.
34. Jankovic BD, Isakovic K, Petrovic S. Effect of pinealectomy on immune reactions in the rat. Immunology 1970; 18 (1) : 1-6.
35. Carrillo-Vico A, Garcia-Perganeda A, Naji L, Calvo JR, Romero MP, Guerrero JM. Expression of membrane and nuclear melatonin receptor mRNA and protein in the mouse immune system. Cell Mol Life Sci 2003; 60 (10) : 2272-8.
36. Poon AM, Liu ZM, Pang CS, Brown GM, Pang SF. Evidence for a direct action of melatonin on the immune system. Biol Signals 1994; 3 (2) : 107-17.
37. Rafii-El-Idrissi M, Calvo JR, Harmouch A, Garcia-Maurino S, Guerrero JM. Specific binding of melatonin by purified cell nuclei from spleen and thymus of the rat. J Neuroimmunol 1998; 86 (2) : 190-7.
38. Dean G, McLoughlin H, Brady R, Adelstein AM, Tallett-Williams J. Multiple sclerosis among immigrants in Greater London. Br Med J 1976; 1 (6014) : 861-4.
39. Hammond SR, English DR, McLeod JG. The age-range of risk of developing multiple sclerosis: Evidence from a migrant population in Australia. Brain 2000; 123 ( Pt 5) : 968-74.
40. Benloucif S, Burgess HJ, Klerman EB, Lewy AJ, Middleton B, Murphy PJ, et al. Measuring melatonin in humans. J Clin Sleep Med 2008; 4 (1) : 66-9.
41. Rudick RA, Cutter G, Baier M, Fisher E, Dougherty D, Weinstock-Guttman B, et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology 2001; 56 (10) : 1324-30.
42. Bergamaschi R, Romani A, Versino M, Poli R, Cosi V. Clinical aspects of fatigue in multiple sclerosis. Funct Neurol 1997; 12 (5) : 247-51.
43. Krupp L. Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease. Mult Scler 2006; 12 (4) : 367-8.
44. Krupp LB, Christodoulou C. Fatigue in multiple sclerosis. Curr Neurol Neurosci Rep 2001; 1 (3) : 294-8.
45. Golan D, Staun-Ram E, Glass-Marmor L, Idit L, Orit R, Sara D, et al. The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis. Brain Behav Immun 2013; 32: 180-5.
46. Golan D, Staun-Ram E, Glass-Marmor L, Idit L, Orit R, Sara D, et al. The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis. Brain Behav Immun 2013; 32: 180-5.